Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Cytotoxic chemotherapy

10 evidence topics · 10 sources

Temozolomide or dacarbazine as the control arm of a randomized phase 2 trial of selumetinib

“Randomized open-label phase II clinical trial comparing selumetinib versus chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“101 patients were randomized on a 1:1 ratio to selumetinib 75 mg orally twice daily on a continual basis (n=50) or chemotherapy (temozolomide 150 mg/m2 orally daily for 5 of every 28 days or DTIC 1000 mg/m2 intravenously every 21 days; investigator choice; n=51) until disease progression, death, intolerable toxicity, or withdrawal of consent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median progression-free survival for those randomized to chemotherapy and selumetinib was 7 (95% CI, 4.3 – 8.4; median treatment duration of 8 weeks (IQR, 4.3–16)) and 15.9 weeks (95% CI, 8.4 – 21.1; median treatment duration of 16.1 weeks (IQR, 8.1–25.3)), respectively (hazard ratio 0.46; 95% CI, 0.30 – 0.71; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median overall survival was 9.1 (95% CI, 6.1 – 11.1) and 11.8 months (95% CI, 9.8 – 15.7) for those randomized to chemotherapy and selumetinib, respectively (hazard ratio 0.66; 95% CI, 0.41–1.06; p=0.09).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No objective responses were observed with chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Temozolomide or dacarbazine versus cabozantinib: randomized phase 2 Alliance A091201 trial

“Alliance for Clinical Trials in Oncology A091201, a randomized phase II trial of the multiple TKI cabozantinib that also inhibits MET and VEGFR2 compared with temozolomide (TMZ) or dacarbazine (DTIC) in patients with metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients with metastatic UM and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (p=0.35), respectively, with median PFS time of 60 and 59 days (p=0.964; HR=0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median overall survival was 6.4 months and 7.3 months (p=0.580; HR=1.21), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Grade 3–4 CTCAE adverse events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2 and 2X, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Intravenous versus hepatic intra-arterial fotemustine: randomized phase 3 EORTC 18021 trial

“The prospective randomized phase III trial (EORTC 18021) thus aimed to compare the efficacy and safety of HIA versus IV fotemustine in UM patients with metastases in liver only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“HIA did not improve OS (median 14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.79–1.50, log-rank P = 0.59.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, there was a significant benefit on PFS for HIA compared with IV with a median of 4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45–0.84, log-rank P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity (4.5%) apart from two toxic deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote